Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: Impact of comorbidities on safety and efficacy outcome

Journal of Chemotherapy

Volumn 17, Issue 6, 2005, Pages 685-692

  Moscetti, L ^a   Nelli, Fabrizio ^a   Padalino, D ^a   Sperduti, I ^b   Giannarelli, D ^b   Pollera, C F ^a  

^a BELCOLLE HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Charlson score; Cisplatin; Comorbidity; Elderly; Gemcitabine; Non small cell lung cancer (NSCLC)

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; GEMCITABINE; SEROTONIN ANTAGONIST;

ADVANCED CANCER; AGE; AGED; AGING; ANEMIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHARLSON SCORE; CHRONIC LUNG DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC CARE; HEART INFARCTION; HUMAN; LIVER DISEASE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PREDICTION; SCORING SYSTEM; SECOND CANCER; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTOPENIA; ULCER; VOMITING;

EID: 30744448981     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.6.685     Document Type: Article

References (27)

1. Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med 1993; 14 (3): 453-478.
2. Hennessy BT, Hanrahan EO, Breathnach OS. Chemotherapy options for the elderly patient with advanced non-small cell lung cancer. Oncologist 2003; 8 (3): 270-277.
3. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of Vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91 (1): 66-72.
4. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95 (5): 362-372.
5. Gillani AA, Grunberg SM. Aerorespiratory tract cancer in older patients. Semin Oncol 2004; 31 (2): 220-233.
6. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17 (11): 3522-3530
7. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20 (21): 4285-4291.
8. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21 (17): 3207-3213.
9. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47 (1): 69-80.
10. Nguyen B, Sandler A, Denham C. The safety and efficacy of gemcitabine plus cisplatin in the elderly chemonaïve NSCLC patients (age ≥70 years) as compared to those with age <70 years. Proc Am Soc Clin Oncol 1999; 18:471a (Abstr 1818).
11. Lippe P, Silva RR, Giuliodori L, et al. Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. Anticancer Res 2002; 22 (2B): 1053-1059.
12. Berardi R, Porfiri E, Scartozzi M, et al. Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 2003; 65 (3): 198-203.
13. Feliu J, Martin G, Madronal C, et al. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 52 (3): 247-252.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method for classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-383.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47 (1): 207-214.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Bunn PA. Treatment of advanced non-small cell lung cancer with two drug combinations. J Clin Oncol 2003; 20 (17): 3565-3567.
18. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol 2004, 22 (2): 330-363
19. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004; 22 (24): 4971-4978
20. Rao AV, Seo PH, Cohen HJ. Geriatric assessment and comorbidity. Semin Oncol 2004; 31 (2): 149-159.
21. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94 (3): 173-181.
22. Kelly K, Giarritta S, Hayes S, et al. Should older patients (pts) receive combinations chemotherapy for advanced non small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20:329a (Abstr 1313).
23. Langer CJ, Vangel M, Schiller J, et al. Age specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70). Lung Cancer 2003; 41:Suppl 2 (Abstr 49).
24. Lilenbaum R, Herndon J, List M, et al. Single agent versus combination chemotherapy in advanced non small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost effectiveness. Proc Am Soc Clin Oncol 2002; 21:1a (Abstr 2).
25. Fossella FV, Belani CP. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first line treatment of advanced/metastatic non small cell lung cancer (NSCLC): analyses in the elderly patients. Proc Am Soc Clin. Oncol 2003; 22: 629 (Abstr 2528).
26. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. New Engl J Med 1999, 341 (27): 2061-2067.
27. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years age or older in clinical trials. J Clin Oncol 2003, 21 (7): 1383-1389.